- Home
- CRIS vs INTS Comparison
CRIS vs INTS Comparison
Compare CRIS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- INTS
- Stock Information
- Founded
- CRIS 2000
- INTS 2012
- Country
- CRIS United States
- INTS United States
- Employees
- CRIS N/A
- INTS N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- INTS Health Care
- Exchange
- CRIS Nasdaq
- INTS Nasdaq
- Market Cap
- CRIS 32.8M
- INTS 33.4M
- IPO Year
- CRIS 2000
- INTS 2023
- Fundamental
- Price
- CRIS $3.23
- INTS $2.21
- Analyst Decision
- CRIS Strong Buy
- INTS Strong Buy
- Analyst Count
- CRIS 3
- INTS 3
- Target Price
- CRIS $23.00
- INTS $8.50
- AVG Volume (30 Days)
- CRIS 33.8K
- INTS 35.2K
- Earning Date
- CRIS 02-18-2025
- INTS 03-13-2025
- Dividend Yield
- CRIS N/A
- INTS N/A
- EPS Growth
- CRIS N/A
- INTS N/A
- EPS
- CRIS N/A
- INTS N/A
- Revenue
- CRIS $10,259,000.00
- INTS N/A
- Revenue This Year
- CRIS N/A
- INTS N/A
- Revenue Next Year
- CRIS N/A
- INTS N/A
- P/E Ratio
- CRIS N/A
- INTS N/A
- Revenue Growth
- CRIS 0.44
- INTS N/A
- 52 Week Low
- CRIS $2.86
- INTS $1.50
- 52 Week High
- CRIS $17.49
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- CRIS 40.93
- INTS 53.65
- Support Level
- CRIS $3.05
- INTS $2.25
- Resistance Level
- CRIS $3.55
- INTS $2.53
- Average True Range (ATR)
- CRIS 0.21
- INTS 0.29
- MACD
- CRIS -0.01
- INTS 0.00
- Stochastic Oscillator
- CRIS 8.33
- INTS 63.59
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.